Biologic therapy of rheumatoid arthritis

Srpski Arhiv Za Celokupno Lekarstvo

Volumn 137, Issue 3-4, 2009, Pages 205-210

  Damjanov, Nemanja ^a   Vojinović, Jelena ^b  

^a INSTITUTE OF RHEUMATOLOGY   (Serbia)

^b Clinical Centre Nis   (Serbia)

Author keywords

Biologic therapy; Juvenile idiopathic arthritis; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; INTERLEUKIN 1; INTERLEUKIN 6; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

DRUG ANTAGONISM; HUMAN; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 66549127479     PISSN: 03708179     EISSN: None     Source Type: Journal    
DOI: 10.2298/SARH0904205D     Document Type: Article

References (44)

1. Mangge H, Vojinovic J, Schaunstein K. Do chemokines spark autoimmunity in juvenile and adult rheumatic disease. Immunobiology. 2002;4:459-71.
2. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK. Severe functional declines, work disability and increased mortality in seventy five RA patients studied over 9 years. Arthritis Rheum. 1984;27:864-72.
3. . Foxwell B, Andreakos E, Brennan F, Feldmann M, Smith C. Prospects for the development of small molecular weight compounds to replace anti-tumor necrosis factor biological agents. Ann Rheum Dis. 2003;62(Suppl II):ii90-ii93.
4. Wolfe F, Pincus T, O'Dell J. Evaluation and documentation of rheumatoid arthritis disease status in the clinic: which variables best predict change in therapy. J Rheumatol. 2001;28:1712-7.
5. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244-57.
6. Fink C. Task force for the classification criteria. A proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol. 1995;22:1566-9.
7. Raveli A. Toward an understanding of the long term outcome of juvenile idiopathic arthritis. Clin Exp Rheum. 2004;22:271-5.
8. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202-9.
9. Vojinović J. Terapija reumatičkih bolesti u detinjstvu. In: Popović M, Stefanovic ́ D, Mitrović D. Reumatička i srodna oboljenja: dijagnoza i terapija. Priručnik: Podsetnik vodič za reumatologe. Atlas iz kliničke reumatologije. Beograd: Vojnoizdavački zavod; 2000. p.682-8.
10. Korpela M, Lassonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease modifying anti-rheumatic drugs. Arthritis Rheum. 2004;50(7):2072-81.
11. Kremer JM, Kil Lee J. The safety and efficacy of the use of methotrexate in long-term therapy in rheumatoid arthritis. Arthritis Rheum. 1986;29:822-31.
12. de Vries-Bouwstra JK, Goekoop-Ruiterman YPM, Verpoot KN, Schreuder GM, Ewals JA, Terwiel JP, et al. Progression of joint damage in early rheumatoid arthritis. Arthritis Rheum. 2008;58:1293-8.
13. . Damjanov N. Biološki lekovi u sistemskim bolestima vezivnog tkiva uloga i značaj. Zbornik uvodnih predavanja XII kongresa alergologa i kliničkih imunologa Srbije i Crne Gore; 2004. p.121-5.
14. Kalden J. Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases. Arthritis Res. 2002;4(Suppl 2):S34-S40.
15. Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol. 2003;15:380-6.
16. . Vojinović J. Imunobiološki principi terapijske primene anti-TNF alfa. Zbornik uvodnih predavanja XII kongresa alergologa i kliničkih imunologa Srbije i Crne Gore; 2004. p.125-8.
17. . Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNF α) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis. 2005; 64(Suppl 4):iv2-14.
18. Dayer JM, Feige U, Edwards III CK, Burger D. Anti-interleukin-1 therapy in rheumatic diseases. Curr Opin Rheumatol. 2001;13(3):170-6.
19. Flannery CR, Little CB, Hughes CE, Curtis CL, Caterson B, Jones SA. IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage. Matrix Biol. 2000; 19:549-53.
20. Manzotti C, Tipping H, Perry LC, Mead KI, Blair PJ, Zheng Y, et al. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory cells. Eur J Immunol. 2002;32:2888-96.
21. Edwards JCW, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology. 1999;97:1868-76.
22. Furst DE, Breedveld J, Kalden J, Smolen JS, Burmester GR, Sieper J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007;66(Suppl III):iii2-iii22.
23. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253-9.
24. Weaver AL, Lautzenheiser RL, Schiff MH, Rubin BR, Polis AB, Tershakovec AM. Real world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: result from the RADIUS observational registry. Curr Med Res Opin. 2006;22:185-98.
25. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet. 2004;363:675-81.
26. Bathon JM, Genovese MC. The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate. Clin Exp Rheumatol. 2003;21(5 Suppl 31):S195-7.
27. van Vollenhaven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis. 2007; 66(7):849-51.
28. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372(9636):375-82.
29. Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC, et al. Long term efficacy and safety of etanercept in children with polyarticular course juvenile rheumatoid arthritis. Arthritis Rheum. 2003;48:218-26.
30. Vojinovic J, Susic G, Damjanov N, Stojanovic R. Serbian etanercept registry. One-year follow-up. Ann Rheum Dis. 2007;66:558-9.
31. Vojinović J. Terapija juvenilnog idiopatskog artritisa. In: Zdravković D, editor. Problemi u pedijatriji 2006. Beograd: Zavod za udžbenike i nastavna sredstva; 2007. p.150-6.
32. Keystone EC. Safety of biologic therapies: an update. J Rheumatol. 2005;74(Suppl):8-12.
33. Listing J, Strangefeld A, Rau R, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in RA patients treated with infliximab or etanercept. Arthritis Rheum. 2005;52(11):3403-12.
34. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36:159-67.
35. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risk of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonist. Ann Rheum Dis. 2005;64:1421-6.
36. Okada SK, Siegal JN. Anti-TNF antibody therapy in RA and risk of serious infections and malignances. JAMA. 2006;296:2201-2.
37. Fleischman R, Stern R, Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2004;4:1333-44.
38. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865-76.
39. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor Antibody: a multi-center, double blind, placebo controlled trial. Arthritis Rheum. 2004;50:1761-9.
40. Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, Dehler S, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum. 2007;56:1417-23.
41. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthitis Rheum. 2006;54:2793-806.
42. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390-400.
43. . Damjanov N, Stefanović D, Ilić T, Prodanović S, Stojanović R. Rituksimab u lečenju reumatoidnog artritisa kliničko ispitivanje kod 12 bolesnika sa aktivnim RA koji prethodno nisu reagovali na lekove koji modifikuju tok bolesti. Acta Rhematologica Belgradensia. 2007; (Suppl 1):72.
44. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American Collage of Rheumatology 2008 recomendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-84.